A novel nanopore sensing platform for real-time detection of hair follicle secretions, enabling non-invasive alopecia diagnosis by analyzing biomarkers like PGD2 and DKK1. Portable, rapid, and highly sensitive, it aims for point-of-care and personalized treatment applications.
The proposed solution is a cutting-edge nanopore sensing platform designed for real-time, non-invasive detection of hair follicle secretions. This innovative technology targets the clinical gap in alopecia diagnosis by enabling the detection of key biomarkers such as PGD2, DKK1, and inflammatory cytokines. By offering a portable, rapid, and highly sensitive diagnostic tool, this platform facilitates early detection and monitoring of hair follicle health, supporting personalized treatment plans and potential point-of-care applications.
Key features:
This technology has achieved Technology Readiness Level 9, indicating it has been proven in operational environments and is ready for commercial deployment. Future validation aims include enhancing multiplexing capabilities and expanding biomarker detection to improve diagnostic accuracy and therapeutic monitoring.
Rutgers University is a comprehensive public research university and New Jersey’s flagship, spanning campuses in New Brunswick–Piscataway, Newark, and Camden. For industry, it offers an integrated clinical and biomedical enterprise through its health system, a statewide extension network for field deployment, and campus-based incubators and pilot-scale facilities that enable prototyping and scale-up. Companies engage through sponsored research, shared core facilities, professional education, and flexible partnership models supported by corporate engagement teams. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, and USDA. A dedicated technology transfer office manages IP, licensing, material transfer, and startup formation, providing clear pathways from lab discovery to market.